Table 1.

Dose levels, number of patients enrolled, and dose-limiting toxicities in cycles 1 and 2

Dose level	Schedule	ABT-888		Topotecan		No. of patients	Dose-limiting toxicities (No. of patients)
		Dose (po BID)	Days	Dose (mg/m²/d IV)	Days
1	A	10 mg	1–7	1.2	C1: −8, 2–5	6	Neutropenia (2), thrombocytopenia (1), febrile neutropenia (1)
					C2 onwards: 1–5
−1	A	10 mg	1–7	0.9	C1: −8, 2–5	3	Neutropenia (2)
					C2 onwards: 1–5
−2	B	10 mg	C1: 2–5	0.75	1–5	3	Febrile neutropenia (1), neutropenia (1)
			C2 onwards: 1–5
−3	B	10 mg	C1: 2–5	0.6	1–5	4^a + 3	None
			C2 onwards: 1–5
1A	C	10 mg	1	0.75	1–5	5	Thrombocytopenia (2)

Abbreviation: C, cycle.

^aOne patient progressed before completing 2 cycles so was not evaluable for toxicity and was therefore replaced.